請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23053完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 江文章(Wenchang Chiang) | |
| dc.contributor.author | Ya-Chi Sun | en |
| dc.contributor.author | 孫雅祺 | zh_TW |
| dc.date.accessioned | 2021-06-08T04:39:38Z | - |
| dc.date.copyright | 2011-08-22 | |
| dc.date.issued | 2011 | |
| dc.date.submitted | 2011-08-16 | |
| dc.identifier.citation | 陳宏彰。2010。薏仁麩皮調節過敏免疫反應之研究及其活性成分之分離與鑑定。國立臺灣大學食品科技研究所博士論文。臺北。
黃丹妮。2010。探討川陳皮素在酵母菌中對紫外線照射引起DNA受損反應的影響。國立臺灣大學食品科技研究所碩士論文。臺北。 劉家余。2010。薏仁麩皮萃取物乙酸乙酯區分層之抗發炎效果。國立臺灣大學食品科技研究所碩士論文。臺北。 Arafa, E. S. A.; Zhu, Q.; Barakat, B. M.; Wani, G.; Zhao, Q.; El-Mahdy, M. A.; Wani, A. A. Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/akt signaling pathway. Cancer Research 2009, 69, 8910-8917. Arber, N.; Eagle, C. J.; Spicak, J.; Racz, I.; Dite, P.; Hajer, J.; Zavoral, M.; Lechuga, M. J.; Gerletti, P.; Tang, J.; Rosenstein, R. B.; Macdonald, K.; Bhadra, P.; Fowler, R.; Wittes, J.; Zauber, A. G.; Solomon, S. D.; Levin, B. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 2006, 355, 885-895. Arico, S. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 Activity in the human colon cancer HT-29 cell line. Journal of Biological Chemistry 2002, 277, 27613-27621. Bartkova, J.; Horejsi, Z.; Koed, K.; Kramer, A.; Tort, F.; Zieger, K.; Guldberg, P.; Sehested, M.; Nesland, J. M.; Lukas, C.; Orntoft, T.; Lukas, J.; Bartek, J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434, 864-870. Bassiouny, A. R.; Zaky, A.; Neenaa, H. M. Synergistic effect of celecoxib on 5-fluorouracil-induced apoptosis in hepatocellular carcinoma patients. Ann. Hepatol. 2010, 9, 410-418. Bertagnolli, M. M.; Eagle, C. J.; Zauber, A. G.; Redston, M.; Solomon, S. D.; Kim, K.; Tang, J.; Rosenstein, R. B.; Wittes, J.; Corle, D.; Hess, T. M.; Woloj, G. M.; Boisserie, F.; Anderson, W. F.; Viner, J. L.; Bagheri, D.; Burn, J.; Chung, D. C.; Dewar, T.; Foley, T. R.; Hoffman, N.; Macrae, F.; Pruitt, R. E.; Saltzman, J. R.; Salzberg, B.; Sylwestrowicz, T.; Gordon, G. B.; Hawk, E. T. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 2006, 355, 873-884. Bonner, W. M.; Redon, C. E.; Dickey, J. S.; Nakamura, A. J.; Sedelnikova, O. A.; Solier, S.; Pommier, Y. [gamma]H2AX and cancer. Nat. Rev. Cancer 2008, 8, 957-967. Bressac, B.; Galvin, K. M.; Liang, T. J.; Isselbacher, K. J.; Wands, J. R.; Ozturk, M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 1973-1977. Buchanan, F. G.; Holla, V.; Katkuri, S.; Matta, P.; DuBois, R. N. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res. 2007, 67, 9380-9388. Capone, M. L.; Tacconelli, S.; Sciulli, M. G.; Patrignani, P. Clinical pharmacology of selective COX-2 inhibitors. Int. J. Immunopathol Pharmacol. 2003, 16, 49-58. Chen, R. Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines. Toxicology and Applied Pharmacology 2000, 169, 132-141. Choi, S.; Hwang, J.; Ko, H.; Park, J.; Kim, S. Nobiletin from citrus fruit peel inhibits the DNA-binding activity of NF-κB and ROS production in LPS-activated RAW 264.7 cells. Journal of Ethnopharmacology 2007, 113, 149-155. Chou, J. H.; Chang, T. T.; Chou, T. C. Models for drug development and drug resistance. The Cancer Handbook 2005, 67, 1-16. Chou, T. C. Theoreticalbasis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews 2006, 58, 621-681. Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research 2010, 70, 440-446. Chuang, H. C.; Kardosh, A.; Gaffney, K. J.; Petasis, N. A.; Schonthal, A. H. COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Molecular Cancer 2008, 7, 1-13. Dannenberg, A.; Altorki, N.; Boyle, J.; Dang, C.; Howe, L.; Weksler, B.; Subbaramaiah, K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. The Lancet Oncology 2001, 2, 544-551. Davis, T. W.; O'Neal, J. M.; Pagel, M. D.; Zweifel, B. S.; Mehta, P. P.; Heuvelman, D. M.; Masferrer, J. L. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res. 2004, 64, 279-285. de Moraes, E.; Dar, N. A.; de Moura Gallo, C. V.; Hainaut, P. Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. International Journal of Cancer 2007, 121, 929-937. Eberhart, C. E.; Coffey, R. J.; Radhika, A.; Giardiello, F. M.; Ferrenbach, S.; DuBois, R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107, 1183-1188. Fitzgerald, G. A. Coxibs and cardiovascular disease. N. Engl. J. Med. 2004, 351, 1709-1711. Gorgoulis, V. G.; Vassiliou, L. V.; Karakaidos, P.; Zacharatos, P.; Kotsinas, A.; Liloglou, T.; Venere, M.; Ditullio, R. A. J.; Kastrinakis, N. G.; Levy, B.; Kletsas, D.; Yoneta, A.; Herlyn, M.; Kittas, C.; Halazonetis, T. D. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434, 904-907. Grosch, S.; Maier, T. J.; Schiffmann, S.; Geisslinger, G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute 2006, 98, 736-747. Grosch, S.; Tegeder, I.; Niederberger, E.; Brautigam, L.; Geisslinger, G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J. 2001, 15, 2742-2744. Gupta, R. A.; Dubois, R. N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001, 1, 11-21. Halazonetis, T. D.; Gorgoulis, V. G.; Bartek, J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319, 1352-1355. Half, E.; Bercovich, D.; Rozen, P. Familial adenomatous polyposis. Orphanet Journal of Rare Diseases 2009, 4, 1-23. Haupt, S.; Kleinstern, J.; Haupt, Y.; Rubinstein, A. Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species. Anticancer Drugs 2006, 17, 609-619. Hayslip, J.; Chaudhary, U.; Green, M.; Meyer, M.; Dunder, S.; Sherman, C.; Salzer, S.; Kraft, A.; Montero, A. J. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC. Cancer 2007, 7, 1-6. Ho, Y. S.; Wang, Y. J.; Lin, J. K. Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. Mol. Carcinog. 1996, 16, 20-31. Horowitz, R. M.; Gentilli, B. Flavonoid constituents of citrus. Citrus Science and Technology 1977, 1, 397-426. Hsiao, P.; Chang, C.; Liu, H.; Tsai, C.; Chiu, T.; Chao, J. Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Toxicology and Applied Pharmacology 2007, 222, 97-104. Huerta, S.; Gao, X.; Livingston, E. H.; Kapur, P.; Sun, H.; Anthony, T. In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201. Surgery 2010, 148, 346-353. Hussain, S. P.; Harris, C. C. Inflammation and cancer: An ancient link with novel potentials. International Journal of Cancer 2007, 121, 2373-2380. Jendrossek, V. Targeting apoptosis pathways by celecoxib in cancer. Cancer Letters 2011, 1-11. Jiricny, J.; Marra, G. DNA repair defects in colon cancer. Curr. Opin. Genet. Dev. 2003, 13, 61-69. Kang, K.; Zhu, C.; Yong, S.; Gao, Q.; Wong, M. Enhanced sensitivity of celecoxib in human glioblastoma cells: induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy. Molecular Cancer 2009, 8, 1-16. Kawabata, K.; Murakami, A.; Ohigashi, H. Nobiletin, a citrus flavonoid, down-regulates matrix metalloproteinase-7 (matrilysin) expression in HT-29 human colorectal cancer cells. Biosci. Biotechnol. Biochem. 2005, 69, 307-314. Kohno, H.; Yoshitani, S. I.; Tsukio, Y.; Murakami, A.; Koshimizu, K.; Yano, M.; Tokuda, H.; Nishino, H.; Ohigashi, H.; Tanaka, T. Dietary administration of citrus nobiletin inhibits azoxymethane-induced colonic aberrant crypt foci in rats. Life Sciences 2001, 69, 901-913. Kondo, Y.; Kanzawa, T.; Sawaya, R.; Kondo, S. The role of autophagy in cancer development and response to therapy. Nature Reviews Cancer 2005, 5, 726-734. Lai, C. S.; Li, S.; Chai, C. Y.; Lo, C. Y.; Ho, C. T.; Wang, Y. J.; Pan, M. H. Inhibitory effect of citrus 5-hydroxy-3,6,7,8,3′,4′-hexamethoxyflavone on 12-O-tetradecanoylphorbol 13-acetate-induced skin inflammation and tumor promotion in mice. Carcinogenesis 2007, 28, 2581-2588. Lai, C. S.; Tsai, M. L.; Cheng, A. C.; Li, S.; Lo, C. Y.; Wang, Y.; Xiao, H.; Ho, C. T.; Wang, Y. J.; Pan, M. H. Chemoprevention of colonic tumorigenesis by dietary hydroxylated polymethoxyflavones in azoxymethane-treated mice. Molecular Nutrition & Food Research 2010, 55, 278-290. Lau, L.; Hansford, L. M.; Cheng, L. S.; Hang, M.; Baruchel, S.; Kaplan, D. R.; Irwin, M. S. Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene 2006, 26, 1920-1931. Lavin, M. F.; Kozlov, S. ATM activation and DNA damage response. Cell Cycle 2007, 6, 931-942. Lee, S. H.; Williams, M. V.; Dubois, R. N.; Blair, I. A. Cyclooxygenase-2-mediated DNA damage. J. Biol. Chem. 2005, 280, 28337-28346. Li, S.; Sang, S.; Pan, M. H.; Lai, C. S.; Lo, C. Y.; Yang, C. S.; Ho, C. T. Anti-inflammatory property of the urinary metabolites of nobiletin in mouse. Bioorganic & Medicinal Chemistry Letters 2007, 17, 5177-5181. Lien, H. M.; Lin, H. W.; Wang, Y. J.; Chen, L. C.; Yang, D. Y.; Lai, Y. Y.; Ho, Y. S. Inhibition of anchorage-independent proliferation and G0/G1 cell-cycle regulation in human colorectal carcinoma cells by 4,7-dimethoxy-5-methyl-l,3-benzodioxole isolated from the fruiting body of antrodia camphorate. Evidence-Based Complementary and Alternative Medicine 2011, 1-10. Lin, M. T.; Lee, R. C.; Yang, P. C.; Ho, F. M.; Kuo, M. L. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. J. Biol. Chem. 2001, 276, 48997-49002. Lin, N.; Sato, T.; Takayama, Y.; Mimaki, Y.; Sashida, Y.; Yano, M.; Ito, A. Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem Pharmacol 2003, 65, 2065-2071. Liu, C. H.; Chang, S. H.; Narko, K.; Trifan, O. C.; Wu, M. T.; Smith, E.; Haudenschild, C.; Lane, T. F.; Hla, T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. Journal of Biological Chemistry 2001, 276, 18563-18569. Luo, G.; Guan, X.; Zhou, L. Apoptotic effect of citrus fruit extract nobiletin on lung cancer cell line A549 in vitro and in vivo. Cancer Biol. Ther. 2008, 7, 966-973. Maier, T. Cyclooxygenase-2 (COX-2)-dependent and independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochemical Pharmacology 2004, 67, 1469-1478. Manthey, J. A.; Guthrie, N. Antiproliferative activities of citrus flavonoids against six human cancer cell lines. J. Agric. Food Chem. 2002, 50, 5837-5843. Marnett, L. J.; DuBois, R. N. COX-2: a target for colon cancer prevention. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 55-80. Middleton, E. J.; Kandaswami, C.; Theoharides, T. C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 2000, 52, 673-751. Milas, L.; Kishi, K.; Hunter, N.; Mason, K.; Masferrer, J. L.; Tofilon, P. J. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. 1999, 91, 1501-1504. Moran, A. E.; Hunt, D. H.; Javid, S. H.; Redston, M.; Carothers, A. M.; Bertagnolli, M. M. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+mice. Journal of Biological Chemistry 2004, 279, 43261-43272. Morley, K.; Ferguson, P.; Koropatnick, J. Tangeretin and nobiletin induce G1 cell cycle arrest but not apoptosis in human breast and colon cancer cells. Cancer Letters 2007, 251, 168-178. Muller, A. C.; Handrick, R.; Elsaesser, S. J.; Rudner, J.; Henke, G.; Ganswindt, U.; Belka, C.; Jendrossek, V. Importance of Bak for celecoxib-induced apoptosis. Biochemical Pharmacology 2008, 76, 1082-1096. Murakami, A.; Koshimizu, K.; Ohigashi, H.; Kuwahara, S.; Kuki, W.; Takahashi, Y.; Hosotani, K.; Kawahara, S.; Matsuoka, Y. Characteristic rat tissue accumulation of nobiletin, a chemopreventive polymethoxyflavonoid, in comparison with luteolin. Biofactors. 2002, 16, 73-82. Murakami, A.; Nakamura, Y.; Ohto, Y.; Yano, M.; Koshiba, T.; Koshimizu, K.; Tokuda, H.; Nishino, H.; Ohigashi, H. Suppressive effects of citrus fruits on free radical generation and nobiletin, an anti-inflammatory polymethoxyflavonoid. BioFactors 2000, 12, 187–192. Niewolik, D.; Vojtesek, B.; Kovarik, J. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 1995, 10, 881-890. Ogino, S.; Kirkner, G. J.; Nosho, K.; Irahara, N.; Kure, S.; Shima, K.; Hazra, A.; Chan, A. T.; Dehari, R.; Giovannucci, E. L.; Fuchs, C. S. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clinical Cancer Research 2008, 14, 8221-8227. Oshima, M.; Dinchuk, J. E.; Kargman, S. L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J. M.; Evans, J. F.; Taketo, M. M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87, 803-809. Ozaki, T.; Nakagawara, A. p53: the attractive tumor suppressor in the cancer research field. Journal of Biomedicine and Biotechnology 2011, 2011, 1-13. Pan, M. H.; Chen, W. J.; Lin-Shiau, S. Y.; Ho, C. T.; Lin, J. K. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells. Carcinogenesis 2002, 23, 1677-1684. Pan, M. H.; Lai, Y. S.; Lai, C. S.; Wang, Y. J.; Li, S.; Lo, C. Y.; Dushenkov, S.; Ho, C. T. 5-Hydroxy-3,6,7,8,3',4'-hexamethoxyflavone induces apoptosis through reactive oxygen species production, growth arrest and DNA damage-inducible gene 153 expression, and caspase activation in human leukemia cells. Journal of Agricultural and Food Chemistry 2007, 55, 5081–5091. Patel, V. A.; Dunn, M. J.; Sorokin, A. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. Journal of Biological Chemistry 2002, 277, 38915-38920. Paul, S.; Rimando, A. M.; Lee, H. J.; Ji, Y.; Reddy, B. S.; Suh, N. Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prevention Research 2009, 2, 650-657. Phillips, R. K. S.; Wallace, M. H.; Lynch, P. M.; Hawk, E.; Gordon, G. B.; Saunders, B. P.; Wakabayashi, N.; Shen, Y.; Zimmerman, S.; Godio, L.; Rodrigues-Bigas, M.; Su, L. K.; Sherman, J.; Kelloff, G.; Levin, B.; Steinbach, G. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002, 50, 857-860. Portugal, J.; Bataller, M.; Mansilla, S. Cell death pathways in response to antitumor therapy. Tumori. 2009, 95, 409-421. Qiu, P.; Dong, P.; Guan, H.; Li, S.; Ho, C. T.; Pan, M. H.; McClements, D. J.; Xiao, H. Inhibitory effects of 5-hydroxy polymethoxyflavones on colon cancer cells. Molecular Nutrition & Food Research 2010a, 54, S244-S252. Qiu, P.; Guan, H.; Dong, P.; Li, S.; Ho, C. T.; Pan, M. H.; McClements, D. J.; Xiao, H. The p53-, Bax- and p21-dependent inhibition of colon cancer cell growth by 5-hydroxy polymethoxyflavones. Molecular Nutrition & Food Research 2010b, 55, 613–622. Rao, C. V.; Kawamori, T.; Hamid, R.; Reddy, B. S. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 1999, 20, 641-644. Reddy, B. S.; Rao, C. V. Colon cancer: a role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs. Drugs Aging 2000, 16, 329-334. Scheers, M. E.; Ekwall, B.; Dierickx, J. P. In vitro long-term cytotoxicity testing of 27 MEIC chemicals on HepG2 cells and comparison with acute human toxicity data. Toxicol. In Vitro 2001, 15, 153–161. Schetter, A. J.; Heegaard, N. H. H.; Harris, C. C. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2009, 31, 37-49. Sedelnikova, O. A.; Bonner, W. M. [gamma]H2AX in cancer cells : A potential biomarker for cancer diagnostics, prediction and recurrence. Cell cycle 2006, 5, 2909-2913. Shirode, A. B.; Sylvester, P. W. Synergistic anticancer effects of combined γ-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFκB signaling. Biomedicine & Pharmacotherapy 2010, 64, 327-332. Sinicrope, F. A.; Gill, S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 2004, 23, 63-75. Solomon, S. D.; Pfeffer, M. A.; McMurray, J. J.; Fowler, R.; Finn, P.; Levin, B.; Eagle, C.; Hawk, E.; Lechuga, M.; Zauber, A. G.; Bertagnolli, M. M.; Arber, N.; Wittes, J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006, 114, 1028-1035. Song, X. Q.; Lin, H. P.; Johnson, A. J.; Tseng, P. H.; Yang, Y. T.; Kulp, S. K.; Chen, C. S. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. Journal of the National Cancer Institute 2002, 94, 585-591. Steinbach, G.; Lynch, P. M.; Phillips, R. K.; Wallace, M. H.; Hawk, E.; Gordon, G. B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; Su, L. K.; Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342, 1946-1952. Swamy, M. V.; Cooma, I.; Patlolla, J. M.; Simi, B.; Reddy, B. S.; Rao, C. V. Modulation of cyclooxygenase2 activities by the combined action of celecoxib and decosahexaenoic acid novel strategies for colon cancer prevention and treatment. Mol. Cancer Ther. 2004, 3, 215-221. Waskewich, C.; Blumenthal, R. D.; Li, H. L.; Stein, R.; Goldenberg, D. M.; Burton, J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Research 2002, 62, 2029-2033. Yao, H. T.; Lin, J. H.; Chiang, M. T.; Chiang, W.; Luo, M. N.; Lii, C. K. Suppressive effect of the ethanolic extract of adlay bran on cytochrome P-450 enzymes in rat liver and lungs. Journal of Agricultural and Food Chemistry 2011, 59, 4306-4314. Zhao, H.; Tanaka, T.; Halicka, H. D.; Traganos, F.; Zarebski, M.; Dobrucki, J.; Darzynkiewicz, Z. Cytometric assessment of DNA damage by exogenous and endogenous oxidants reports aging-related processes. Cytometry A. 2007, 71, 905-914. Zhao, S.; Cai, J.; Bian, H.; Gui, L.; Zhao, F. Synergistic inhibition effect of tumor growth by using celecoxib in combination with oxaliplatin. Cancer Invest. 2009, 27, 636-640. Zhu, J.; Huang, J. W.; Tseng, P. H.; Yang, Y. T.; Fowble, J.; Shiau, C. W.; Shaw, Y. J.; Kulp, S. K.; Chen, C. S. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004, 64, 4309-4318. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23053 | - |
| dc.description.abstract | 川陳皮素為分離自柑橘類果皮之多甲氧基黃酮類化合物，可抑制癌細胞COX-2 表現與導致細胞週期停滯。celecoxib 為非類固醇止痛消炎藥 (non-steroidal anti-inflammatory drug, NSAID)，為美國食品藥物管理局認可做為輔助性治療家族性大腸息肉症 (familial adenomatous polyposis, FAP) 之藥物。celecoxib 具有導致腸胃道不適與增加心血管毒性之副作用。本實驗希望藉由川陳皮素與celecoxib 共同處理以減緩藥物副作用。實驗設計以HT-29 與COLO-205 人類大腸癌細胞株為模式，分析不同濃度celecoxib、川陳皮素與共同處理對細胞生長抑制之影響，propidium iodide 及annexin V/PI 染色法分析細胞週期與細胞凋亡，西方墨點法與免疫螢光染色法分析組蛋白H2AX 之磷酸化程度。結果顯示，添加川陳皮素於較低濃度celecoxib 對細胞生長抑制具有相加 (additive effect) 或加乘效果 (synergistic effect)，且於75 μM celecoxib 與50 μM 川陳皮素的組合有較佳加乘效果。celecoxib 與川陳皮素的共同處理可以增加DNA 損傷反應γH2AX 的表現，同時可抑制細胞增生與促進細胞凋亡。以上結果證實，celecoxib 與川陳皮素的共同處理具有提升大腸癌治療效果且可避免高劑量celecoxib 處理所導致毒性之潛力。 | zh_TW |
| dc.description.abstract | Nobiletin, a polymethoxyflavones isolated from citrus peels, could inhibit the COX-2 expression in various cancer cells and lead to cell cycle arrest. A non-steroidal anti-inflammatory drug (NSAID), celecoxib has been approved by the US Food and Drug Administration for the adjunctive therapy in patients with familial adenomatous polyposis (FAP) or colon cancer. However, celecoxib treatment causes undesired side effects, including gastrointestinal and cardiovascular toxicities. Thus, it would be beneficial if combination treatment to provide enhanced therapeutic response and reduce the side effects of medication. HT-29 and COLO-205 human colon cancer cells exposed to various doses of celecoxib, nobiletin and co-treated with both agents were analyzed for cell proliferation, cell cycle analysis by propidium iodide staining, apoptosis analysis by annexin V/PI staining and γH2AX expression by immunofluorescence and western blotting analysis. Our results show that adding nobiletin to subtoxic celecoxib could synergistically or additively inhibit cell proliferation. Particularly, 75 μM celecoxib together with 50 μM nobiletin indicated the synergistic effect. Combining celecoxib with nobiletin significantly increases DNA damage signal, γH2AX levels and concurrently inhibits cell proliferations and promotes cell death by apoptosis. These results suggest that celecoxib-nobiletin co-treatment may provide enhanced therapeutic response in colon cancer cells, while avoiding the toxicity associated with high-dose celecoxib treatment. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T04:39:38Z (GMT). No. of bitstreams: 1 ntu-100-R98641031-1.pdf: 5296107 bytes, checksum: f30e360ea3059602bbea41514d270740 (MD5) Previous issue date: 2011 | en |
| dc.description.tableofcontents | 第一章 前言 1
第二章 文獻回顧 2 一、 多甲氧基黃酮類 2 (一) 多甲氧基黃酮類之生物活性 2 (二) 川陳皮素及其多甲氧基黃酮類之抗發炎研究 4 (三) 川陳皮素及其多甲氧基黃酮類之大腸癌研究 7 二、 藥物合併使用之觀念 10 (一) 藥物臨床使用之困境 10 (二) 藥物合併使用之益處 10 (三) 評估藥物間交互作用之方法 12 三、 第二型環氧酶抑制劑可做為癌症治療藥物 13 (一) 第二型環氧酶在癌症的重要性 13 (二) 第二型環氧酶抑制劑可做為癌症用藥 15 (三) celecoxib 在臨床上之效用 15 (四) celecoxib 造成腸胃道不適與增加心血管疾病風險 19 四、 發炎反應與DNA 損傷反應之機制探討 21 (一) 抗癌治療之多種細胞死亡途徑 25 (二) 腫瘤抑制蛋白p53 在細胞凋亡與DNA 損傷上 之角色 27 第三章 研究動機與實驗架構 29 一、 研究動機 29 二、 實驗架構 30 第四章 材料與方法 31 一、 實驗材料 31 (一) 實驗樣品 31 (二) 實驗細胞株 31 (三) 化學藥品與試劑 32 (四) 儀器設備 35 二、 實驗方法 37 (一) 細胞培養 (Cell culture) 37 (二) 細胞存活率測定 (MTT assay) 38 (三) 組合指數分析 (Combination index assay) 38 (四) 錐藍染色法 (Trypan blue assay) 40 (五) 細胞週期分析 (Cell cycle analysis) 40 (六) 細胞凋亡雙染檢測 (Annexin V-FITC/PI staining) 41 (七) 免疫螢光染色法 (Immunofluorescent staining) 42 (八) 蛋白質萃取 (Protein extraction) 43 (九) 聚丙烯醯胺膠體電泳法 (SDS-PAGE assay) 43 (十) 西方墨點法 (Western blotting) 44 (十一) 吖啶橙染色法 (Acridine orange staining) 46 三、 統計分析 (Statistics analysis) 46 第五章 實驗結果 47 一、 celecoxib 對HT-29 與COLO-205 人類大腸癌細 胞株生長抑制作用 47 二、 nobiletin對HT-29 與COLO-205 人類大腸癌細胞 株生長抑制作用 49 三、 celecoxib 與nobiletin 共同處理能增加細胞生長抑 制效果 51 四、 celecoxib 與nobiletin 共同處理對細胞週期與細胞 凋亡之影響 55 五、 celecoxib 與nobiletin 共同處理對抗發炎反應相關 蛋白之影響 63 六、 celecoxib 與nobiletin共同處理可增加DNA 損傷 指標γH2AX 表現 65 第六章 討論 71 一、 celecoxib 與nobiletin 共同處理對腸癌細胞生長抑 制作用 71 二、 celecoxib 與nobiletin 共同處理對細胞週期與細胞 凋亡之影響 73 三、 celecoxib 與nobiletin 共同處理對p53 表現之影響 76 四、 celecoxib 與nobiletin 共同處理對發炎反應之影響 78 五、 celecoxib 與nobiletin 共同處理對DNA 損傷之 影響 78 六、 比較HT-29 與COLO-205 人類大腸癌細胞株之實 驗結果 81 第七章 結論 86 第八章 參考文獻 87 第九章 補充資料 97 | |
| dc.language.iso | zh-TW | |
| dc.title | 川陳皮素合併celecoxib 抑制腸癌細胞生長之機制探討 | zh_TW |
| dc.title | Combination effects of nobiletin and celecoxib on the growth inhibition of colon cancer cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 99-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.coadvisor | 施純光(Chun-Kuang Shih),羅翊禎(Yi-Chen Lo) | |
| dc.contributor.oralexamcommittee | 何其儻(Chi-Tang Ho),郭靜娟(Ching-Chuan Kuo),謝淑貞(Shu-Chen Hsieh) | |
| dc.subject.keyword | 川陳皮素,celecoxib,DNA 損傷,γH2AX,細胞凋亡, | zh_TW |
| dc.subject.keyword | nobiletin,celecoxib,DNA damage,γH2AX,apoptosis, | en |
| dc.relation.page | 98 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2011-08-17 | |
| dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
| dc.contributor.author-dept | 食品科技研究所 | zh_TW |
| 顯示於系所單位： | 食品科技研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-100-1.pdf 目前未授權公開取用 | 5.17 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。